A response was seen in 8 patients, with 3 patients achieving transfusion independence,168 the phase 1b study conducted subsequently, included 6 out of 44 patients with SRSF2 mutations, 4 with SF3B1, and 6 with LR‐MDS. Here, SF3B1 is linked to myelodysplastic syndrome.